Download Dupuytren’s Contracture

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Dental emergency wikipedia , lookup

List of medical mnemonics wikipedia , lookup

Transcript
Dupuytren’s Contracture
1
Dupuytren’s Contracture
 Fibrous tissue of the palmar fascia to
shorten and thicken
 Common in men older than 40 years; in
persons of Northern European descent; and
in persons who smoke, use alcohol, or have
diabetes (3 to 33 %)
 Present with a small, pitted nodule (or
multiple nodules) on the palm, which slowly
progresses to contracture of the fingers
 Progresses' faster in <50 yr olds
 Smoking and alcohol use increase the
chance that surgery will be needed
2
Dupuytren’s
Contracture
 Found on the palm of the
hand proximal to the
metacarpo-phalangeal
 Grade 1 disease presents
(MCP) joint. Can be
as a thickened nodule
bilateral
and a band in the palmar
aponeurosis; this band
 Patients usually have
may progress to skin
difficulty with tasks such
tethering, puckering, or
as face washing, hair
pitting.
combing, and putting
their hands in their
 Grade 2 presents as a
pockets.
peritendinous band, and
extension of the affected
 Note the site of the
finger is limited.
nodule and the presence
of contractures; bands;
 Grade 3 presents as
and skin pitting,
flexion contracture
tenderness, and dimpling.
3
Fibromyalgia
4
 Characteristic features:
 Chronic widespread pain for at least
three monthsTender points in 11 of 18
specific anatomic locations
 Associated features
 Anxiety
 Cognitive difficulties
 Fatigue
 Headache (50%) (migraine)*
 Paresthesias, morniing stiffness
 Sleep disturbance
*?a defect in the serotonergic and
adrenergic systems
5
Associated Findings
 History of trauma,

childhood abuse, anxiety,
depression, or sleep

disorder (alpha frequency
rhythm, termed alpha-delta 

sleep anomaly )

 Patients with high tender
point counts are more likely 
to report adverse childhood
experiences like loss of a

parent or abuse

 Irritable bowel syndrome
(IBS)
Other disorders commonly
associated with FM include:
Irritable bladder
Dysmenorrhea
Premenstrual syndrome
Restless leg syndrome
Temporomandibular joint
pain
Noncardiac chest pain
Raynaud's phenomenon
and Sicca syndrome
(Sjogren’s)
6
Other
Diagnoses/Associated
 Myofascial pain syndrome,
 Chronic fatigue syndrome, and
 Hypothyroidism.
7
Myofascial pain syndrome
 Characterized by painful, tender areas in
the muscles.
 It is a localized disorder without any
systemic manifestations.
 It commonly affects the axial muscles.
 In contrast to the widespread pain of
fibromyalgia, the pain in myofascial pain
syndrome arises from trigger points in
individual muscles.
 On examination, the presence of trigger
points is characteristic of myofascial pain
syndrome.
8
Chronic fatigue syndrome
(CFS)
 Chronic pain and fatigue are common to
chronic fatigue syndrome and fibromyalgia.
 CFS an ongoing subclinical inflammatory
process manifested by low-grade fever,
lymph gland enlargement, and acute onset
of the illness, whereas there is no evidence
of inflammatory response in fibromyalgia.
9
Hypothyroidism
 Manifested by profound fatigue, muscle
weakness, and generalized malaise, closely
resembles fibromyalgia.
 Patients need to be examined for clinical signs
of thyroid dysfunction and, if in doubt, thyroid
function tests should be ordered to rule out
hypothyroidism.
 (The differential diagnosis also might include
metabolic and inflammatory myopathies
(especially in patients taking statins),
polymyalgia rheumatica, and other rheumatic
diseases. )
10
 optimal intervention is an approach that
also includes nonpharmacologic treatments,
specifically exercise and cognitive behavior
therapy
 education, cognitive behavior strategies,
physical training, and medications for
treatment of fibromyalgia
11
FIBROMYALGIA-Review
Multi symptom
condition
12
Multi symptom condition
characterized by chronic widespread
pain
Muscular pain
Fatigue
Sleep abnormalities
Joint pain
Headaches
Restless legs
Numbness
Impaired memory
Leg cramps
Impaired
concentration
Nervousness
Major depression
13
Patient-Reported Symptoms at
Diagnosis of Fibromyalgia
14
15
Features
3 months or longer in all 4 quadrants of the body,
but not centered in the joints
Lower pain threshold:
Allodynia-pain from normally non noxious stimuli
Hyperalgesia-increased response to painful stimuli
Under diagnosed and undertreated
(Prevalence:2% to 4%)/
Onset usually at 20 to 55 years/ F:M 9:1
First-degree relatives of FM patients have 8 times
the risk
16
?etiology
Pain amplification
Lower levels of metabolites of serotonin and
norepinephrine in their cerebrospinal fluid
Increased levels of pro-nociceptive
transmitters substance P and glutamate that
amplify pain impulses
17
No objective laboratory test or marker
exists, diagnosis is based on history and
physical examination
Chronic Widespread Pain for at least 3
months and pain on at least 11 of 18
specified muscle tendon sites of focal
tenderness (“tender points” 11/18)
Use of a structured interview with questions
about generalized fatigue, headache, sleep
disturbance, neuropsychiatric complaints,
numbness or tingling, and irritable bowel
symptoms.
18
POINTS OF TENDERNESS
19
?TREATMENT Eval Criteria
SYMPTOM
CRITICAL FOR EVAL%
Pain
100
Fatigue
94
Patient global
improvement
94
Multidimensional function
86
Tenderness
74
Sleep
66
Health-related quality of life
65
Dyscognition
61
Stiffness
60
20
Current Knowledge About
Pharmacotherapies
‘Off label’
SNRIs
Anticonvulsants
Tricyclic
antidepressants (TCAs)
Muscle relaxants
SSRIs
Opioids
Nonsteroidal antiinflammatory drugs
(NSAIDs) and
Cyclo-oxygenase
(COX2) inhibitors
 FDA ‘approved’
 Pregabalin(Lyrica)
 Duloxetine
Hydrochloride (Cymbalta)
 Milnacipran
Hydrochloride(Savella)
21
Pregabalin
(Lyrica)
Duloxetine
Hydrochloride
(Cymbalta)
Milnacipran
Hydrochloride
(Savella)
Alpha2 receptor
SNRI
SNRI
150-225 mg bid
75 mg bid
May increase to 150 mg
bid within 1 wk
Maximum dose 225 mg
bid
60 mg/d
Start 30 mg/d for 1
wk, increase to 60
mg/d
50 mg bid (start 12.5
mg/d, increase on day 2
to 12.5 mg bid,
on day 4 to 25 mg bid,
after day 7 to 50 mg bid)
Maximum dose 200 mg/d
Angioedema,
hypersensitivity
reactions, peripheral
edema
Suicidality, orthostatic
hypotension, serotonin
syndrome
Suicidality, orthostatic
hypotension, serotonin
syndrome
Dizziness, somnolence,
dry mouth, edema,
blurred vision, weight
gain, difficulty with
concentration/attention
Nausea, dry mouth,
constipation,
somnolence,
hyperhidrosis,
decreased appetite
Nausea, headache,
constipation,
dizziness, insomnia, hot
flush, hyperhidrosis,
vomiting, palpitations,
heart rate increase, dry
mouth, hypertension
22